Literature DB >> 6759080

The long-term effects of chlorpropamide on insulin, C-peptide, and proinsulin secretion.

R S Elkeles, L G Heding, R B Paisey.   

Abstract

It had been suggested that long-term lowering of blood glucose by sulfonylureas in non-insulin-dependent (NIDD) diabetes is not due to a sustained increase in insulin secretion. We have re-examined this question. Thirteen nonobese NIDD patients not controlled on diet alone were studied prospectively on treatment with chlorpropamide for over 3 mo. Of these, 9 were also studied after 1 yr. Improvement in glucose tolerance was associated with an increase in fasting and postglucose serum insulin and C-peptide concentration. We conclude that at least for over 1 yr chlorpropamide increases insulin secretion. After 3 and 12 mo the fasting proinsulin percentage of immunoreactive insulin was increased.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6759080     DOI: 10.2337/diacare.5.4.427

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  6 in total

1.  Diet only or diet and sulfonylureas in mild type II diabetes (NIDDM)? Pathophysiologic and therapeutic implications.

Authors:  I R Sinay; P Arias; M A Schnitman; S A Damilano; M C Faingold; J A Moguilevsky
Journal:  Acta Diabetol Lat       Date:  1988 Oct-Dec

Review 2.  Oral hypoglycaemic agents. An update.

Authors:  A C Asmal; A Marble
Journal:  Drugs       Date:  1984-07       Impact factor: 9.546

Review 3.  Adverse cardiovascular effects of sulphonylurea drugs. Clinical significance.

Authors:  R Huupponen
Journal:  Med Toxicol       Date:  1987 May-Jun

4.  Sulphonylurea therapy doubles B-cell response to glucose in type 2 diabetic patients.

Authors:  J P Hosker; M A Burnett; E G Davies; E A Harris; R C Turner
Journal:  Diabetologia       Date:  1985-11       Impact factor: 10.122

Review 5.  Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update.

Authors:  P Marchetti; R Navalesi
Journal:  Clin Pharmacokinet       Date:  1989-02       Impact factor: 6.447

6.  Effects of Glimepiride vs Glibenclamide on Ischaemic Heart Disease Risk Factors and Glycaemic Control in Patients with Type 2 Diabetes Mellitus.

Authors:  M E Britton; A E Denver; V Mohamed-Ali; J S Yudkin
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 3.580

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.